https://www.selleckchem.com/products/U0126.html
BACKGROUND Folate supplementation treatment is the first-line therapy in hyperhomocysteinaemia (HHcy). Up to 40% of HHcy patients do not benefit from folate therapy. Genetic and epigenetic factors of one-carbon metabolism (1-CM) might be identified as a predictor of folate supplementation treatment response. In the present study, we attempt to identify whether genetic and epigenetic factors might predict folate treatment response. METHODS A total of 230 patients with HHcy were involved in this prospective cohort study. Differences between
Aimer
Commentaire
Partagez
